LXEO Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. (LXEO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $116.2K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Tamayo Louis Edward | Chief Financial Officer | Sell | 4,117 | $4.91 | $20.2K | 92,907 −4.2% of holding | |
| Townsend Richard Nolan | Chief Executive Officer | Sell | 3,345 | $4.95 | $16.6K | 374,472 −0.9% of holding | |
| Otero Jose Manuel | Chief Operating Officer | Sell | 1,304 | $4.96 | $6.5K | 136,178 −0.9% of holding | |
| Townsend Richard Nolan | Chief Executive Officer | Sell | 25,947 | $4.48 | $116.2K | 377,817 −6.4% of holding | |
| Bhalla Narinder Pal | Chief Medical Officer | Sell | 22,306 | $4.42 | $98.6K | 82,194 −21.3% of holding | |
| Otero Jose Manuel | Chief Operating Officer | Sell | 4,666 | $4.48 | $20.9K | 137,482 −3.3% of holding | |
| Tamayo Louis Edward | Chief Financial Officer | Sell | 4,641 | $4.49 | $20.8K | 97,024 −4.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.